Hospital Universitario Virgen de la Victoria -ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2023

  1. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

    HemaSphere, Vol. 7, Núm. 1, pp. E818

2022

  1. Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera (Annals of Hematology, (2022), 101, 10, (2231-2239), 10.1007/s00277-022-04963-z)

    Annals of Hematology

  2. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis

    Cancers, Vol. 14, Núm. 9

  3. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239

  4. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

    British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538

  5. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

    Cancer, Vol. 128, Núm. 13, pp. 2441-2448

2017

  1. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis

    European Journal of Haematology, Vol. 98, Núm. 4, pp. 407-414